The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis

Wang, Tongya; Li, Changyang; Li, Xiang; Zhai, Jing; Wang, Shoulin; Shen, Lizong

doi:10.1186/s40001-022-00878-7

Table 1 The characteristics of the enrolled clinical trials in this systematic review and network meta-analysis

From: The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis

Authors	Country	Study start and end time	Intervention group			Control group
Authors	Country	Study start and end time	NAC/cycles	Pat	Postoperative/cycles	NAC/cycles	Pat	Postoperative/cycles
Cunningham et al. [4]	UK	1994.7–2002.4	Epirubicin + cisplatin + fluorouracil/3	250	Epirubicin + cisplatin + fluorouracil/3	NA	253	NA
Schuhmacher et al. [9]	Germany	1999.7–2004.2	Cisplatin + fluorouracil/2	72	NA	NA	72	NA
Ychou et al. [17]	France	1995.11–2003.12	Cisplatin + fluorouracil/3	113	Cisplatin + fluorouracil/3	NA	111	NA
Biffi et al. [18]; Fazio et al. [19]	Italy	1999.11–2005.11	Docetaxel + cisplatin + fluorouracil/4	34	NA	NA	35	Docetaxel + cisplatin + fluorouracil/4
Yoshikawa et al. [20, 21]	Japan	2009.10–2011.7	Cisplatin + S-1/2–4	41	S-1 (6–12 m)	Cisplatin + paclitaxel/2–4	42	S-1 (6–12 m)
Xue et al. [22]	China	2011.09–2012.12	Oxaliplatin + S-1/oxaliplatin + capecitabine/2	50	Oxaliplatin + S-1/oxaliplatin + capecitabine/6	NA	50	Oxaliplatin + S-1/oxaliplatin + capecitabine/8
Al-Batran et al. [23, 24]	Germany	2010.8–2015.2	Epirubicin + cisplatin + fluorouracil/capecitabine/3	360	Epirubicin + cisplatin + fluorouracil/capecitabine/3	Docetaxel + oxaliplatin + fluorouracil/4	356	Docetaxel + oxaliplatin + fluorouracil 4
Hayashi et al. [26]	Japan	2011.10–2014.9	Cisplatin + S-1/2–4	62	S-1 (12 m)	Docetaxel + cisplatin + S-1 (2–4)	65	S-1 (12 m)
Sah et al. [27]	China	2018.8–2020.3	Docetaxel + oxaliplatin + fluorouracil/4	40	Docetaxel + oxaliplatin + fluorouracil/NA	Oxaliplatin + S-1/3	34	Oxaliplatin + S-1/NA
Terashima et al. [28]; Iwasaki et al. [29]	Japan	2005.10–2013.7	Cisplatin + S-1/2	151	S-1/8	NA	149	S-1/8
Kang et al. [30]	Korea	2012.1–2017.1	Docetaxel + oxaliplatin + S-1/3	238	S-1/	NA	246	S-1/8
Zhang et al. [31]	China	2012.8–2017.2	Oxaliplatin + S-1/3	337	Oxaliplatin + S-1/5	NA	685	Oxaliplatin + S-1/capecitabine/8

NAC neoadjuvant chemotherapy, Pat patient number

Back to article page

ISSN: 2047-783X

Contact us

Submission enquiries: jacinth.kennady@springernature.com
General enquiries: info@biomedcentral.com

European Journal of Medical Research

Contact us